Cagrilintide has a 7–9 day half-life, enabling weekly subcutaneous dosing

Cagrilintide downstream effects extend beyond appetite suppression: it activates AMPK

Cagrilintide biomarkers measure peptide response through glucose, insulin, leptin, and

Cagrilintide activates amylin receptors in the area postrema to slow

Cagrilintide gene expression involves GLP-1 and amylin pathways regulating appetite,

Cagrilintide shows promise in animal models but human trial data

Cagrilintide bioavailability reaches 80% via subcutaneous injection, with peak plasma

Cagrilintide metabolism research reveals dual amylin-calcitonin receptor activation extends half-life

Survodutide activates both GLP-1 and glucagon receptors simultaneously — a

Survodutide binds both GLP-1 and glucagon receptors with equal affinity,

Survodutide’s half-life exceeds seven days, enabling weekly dosing while maintaining

Survodutide biomarkers track GLP-1/glucagon dual receptor engagement through HbA1c, hepatic

Survodutide downstream effects include enhanced insulin sensitivity, reduced hepatic steatosis,

Survodutide gene expression activates dual GLP-1/glucagon receptors, driving metabolic shifts

Survodutide metabolism research reveals dual GLP-1/glucagon receptor activation with extended

Survodutide bioavailability ranges from 45–68% depending on injection site, fat

Survodutide activates both GLP-1 and glucagon receptors simultaneously — a

Survodutide animal vs human research shows dual GIP/GLP-1 agonism produces

Mazdutide’s dual GLP-1/glucagon receptor activation shows 20–25% weight loss in

Mazdutide pharmacokinetics reveal a five-day half-life allowing weekly dosing with

Mazdutide binds both GLP-1 and glucagon receptors simultaneously, creating synergistic